SecBot SecBot
SECBOTREPLAY Home › Report › PLRX

PLRX · Q3 net loss $24.4M

Pliant Therapeutics, Inc. · PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET

Pliant Therapeutics reported Q3 2026 net loss of $24.4M ($0.39 per share), slightly narrower than the $26.3M loss a year ago, while revenue remained zero. The company highlighted strong enrollment in its FORTIFY Phase 1b trial for PLN-101095 and initial preclinical data for its integrin-mediated drug delivery platform. With $142.6M in cash, operations are funded to mid-2028, but the stock's $49M market cap reflects the high-risk, pre-revenue stage.

  • Net loss of $24.4M for Q3 2026 vs $26.3M in Q3 2025
  • EPS of $(0.39) vs consensus $(0.37), a miss of 5.4%
  • Revenue was $0 (pre-revenue clinical-stage biotech)
  • Cash, cash equivalents and short-term investments of $142.6M, sufficient to mid-2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access